London · Delayed Price · Currency is GBP · Price in GBX 4basebio Statistics
Total Valuation
4basebio has a market cap or net worth of GBP 81.58 million. The enterprise value is 80.26 million.
| Market Cap | 81.58M |
| Enterprise Value | 80.26M |
Important Dates
The next estimated earnings date is Friday, June 26, 2026.
| Earnings Date | Jun 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
4basebio has 15.54 million shares outstanding. The number of shares has increased by 18.24% in one year.
| Current Share Class | 15.54M |
| Shares Outstanding | 15.54M |
| Shares Change (YoY) | +18.24% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 11.74% |
| Owned by Institutions (%) | 40.68% |
| Float | 5.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 48.19 |
| PB Ratio | 8.07 |
| P/TBV Ratio | 10.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 47.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.31, with a Debt / Equity ratio of 1.65.
| Current Ratio | 7.31 |
| Quick Ratio | 6.91 |
| Debt / Equity | 1.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.04 |
| Interest Coverage | -18.79 |
Financial Efficiency
Return on equity (ROE) is -92.65% and return on invested capital (ROIC) is -30.44%.
| Return on Equity (ROE) | -92.65% |
| Return on Assets (ROA) | -28.04% |
| Return on Invested Capital (ROIC) | -30.44% |
| Return on Capital Employed (ROCE) | -62.36% |
| Weighted Average Cost of Capital (WACC) | 8.20% |
| Revenue Per Employee | 12,093 |
| Profits Per Employee | -120,750 |
| Employee Count | 110 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 1.39 |
Taxes
| Income Tax | -698,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.18% in the last 52 weeks. The beta is 0.87, so 4basebio's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -45.18% |
| 50-Day Moving Average | 497.85 |
| 200-Day Moving Average | 625.15 |
| Relative Strength Index (RSI) | 58.21 |
| Average Volume (20 Days) | 2,227 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4basebio had revenue of GBP 1.69 million and -16.91 million in losses. Loss per share was -1.09.
| Revenue | 1.69M |
| Gross Profit | 974,000 |
| Operating Income | -16.66M |
| Pretax Income | -17.60M |
| Net Income | -16.91M |
| EBITDA | -15.75M |
| EBIT | -16.66M |
| Loss Per Share | -1.09 |
Balance Sheet
The company has 18.04 million in cash and 16.72 million in debt, with a net cash position of 1.32 million or 0.09 per share.
| Cash & Cash Equivalents | 18.04M |
| Total Debt | 16.72M |
| Net Cash | 1.32M |
| Net Cash Per Share | 0.09 |
| Equity (Book Value) | 10.11M |
| Book Value Per Share | 0.65 |
| Working Capital | 17.84M |
Cash Flow
In the last 12 months, operating cash flow was -15.59 million and capital expenditures -470,000, giving a free cash flow of -16.06 million.
| Operating Cash Flow | -15.59M |
| Capital Expenditures | -470,000 |
| Depreciation & Amortization | 940,000 |
| Net Borrowing | -400,000 |
| Free Cash Flow | -16.06M |
| FCF Per Share | -1.03 |
Margins
| Gross Margin | 57.53% |
| Operating Margin | -984.29% |
| Pretax Margin | -1,039.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
4basebio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.24% |
| Shareholder Yield | -18.24% |
| Earnings Yield | -20.72% |
| FCF Yield | -19.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for 4basebio is 1,700.00, which is 240.00% higher than the current price. The consensus rating is "Buy".
| Price Target | 1,700.00 |
| Price Target Difference | 240.00% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 145.34% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
4basebio has an Altman Z-Score of 0.54 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.54 |
| Piotroski F-Score | 1 |